Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant700 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,395 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05924841 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 100 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06726148 | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Novartis PharmaceuticalsINDUSTRY | 16 | Aug 27, 2026 |
| clinicaltrials |
| NCT06577987 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | active not recruiting | Phase 1 | 220 | Circle PharmaINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07561645 | A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung(ALPINE 2) | not yet recruiting | Phase 2 | 75 | Technische Universität DresdenOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT03206060 | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) | recruiting | Phase 1 | 110 | Moonlight Bio, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784595 | Comparison of an Initial Active Follow-up and Therapeutic Care on Functional Outcome and Quality of Life in Patients With Head and Neck Paragangliomas(PRONO-PARAG-N) | not yet recruiting | N/A | 122 | Hospices Civils de LyonOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07739758 | A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | recruiting | Phase 3 | 442 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05963867 | A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer | recruiting | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | recruiting | Phase 1 | 339 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 3 | Aug 21, 2026 | clinicaltrials |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05064150 | Neuroendocrine Tumors - Patient Reported Outcomes(NET-PRO) | active not recruiting | — | 2,539 | University of IowaOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07274657 | Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy(SMILE) | recruiting | N/A | 150 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT06922539 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer | recruiting | Phase 1 | 44 | SciTech Development, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer(ALISCA-Lung1) | recruiting | Phase 2 | 120 | Puma Biotechnology, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06745323 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC(DeLLphi-309) | active not recruiting | Phase 2 | 252 | AmgenINDUSTRY | 16 | Aug 17, 2026 | clinicaltrials |
| NCT06768307 | Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06377033 | Using the EHR to Advance Genomic Medicine Across a Diverse Health System | recruiting | N/A | 1,000 | University of PennsylvaniaOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02688894 | The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S] | recruiting | — | 797 | Samsung Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04199741 | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | recruiting | Phase 1 / Phase 2 | 105 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04609592 | Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | active not recruiting | Phase 1 | 10 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05552846 | Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy | recruiting | N/A | 104 | Ruijin HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759856 | NK Cells Plus ICI for SCLC Maintenance(NK-ICI-SCLC) | recruiting | Phase 2 | 42 | Tianjin First Central HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759960 | Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors | recruiting | N/A | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04993261 | An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | active not recruiting | Early Phase 1 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06807632 | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | recruiting | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients(COMPETE) | active not recruiting | Phase 3 | 324 | ITM Solucin GmbHINDUSTRY | 14 | Aug 7, 2026 | clinicaltrials |
| NCT04280081 | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation(LIBRETTO-321) | active not recruiting | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07151391 | The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) | recruiting | Phase 2 | 86 | University of UtahOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT06056895 | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma(TRICK-MCC) | active not recruiting | Phase 2 | 12 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT06941480 | A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate | not yet recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07468656 | SCLC Tarlatamab Blood Collection | not yet recruiting | — | 25 | Duke UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT05879978 | A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | active not recruiting | Phase 1 | 45 | Boehringer IngelheimINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06486428 | Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies(SUCCEED) | active not recruiting | — | 22 | Addario Lung Cancer Medical InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2026source: clinicaltrials